{"disease":{"id":"nsclc-recurrent","name":"nsclc recurrent"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05701787","title":"Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT04492969","title":"Prospective Observation of Failure Patterns in NSCLC Treated With ICIs","phase":"","overall_status":"UNKNOWN","enrollment_count":320,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04027647","title":"Phase 2 Study of Dacomitinib in NSCLC","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":118,"lead_sponsor_name":"National Cancer Centre, Singapore","has_results":false},{"nct_id":"NCT07410494","title":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT04768491","title":"Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC","phase":"","overall_status":"UNKNOWN","enrollment_count":82,"lead_sponsor_name":"Peking Union Medical College","has_results":false},{"nct_id":"NCT05274451","title":"A Study to Investigate LYL797 in Adults With Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":57,"lead_sponsor_name":"Lyell Immunopharma, Inc.","has_results":false},{"nct_id":"NCT04636775","title":"Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)","phase":"","overall_status":"UNKNOWN","enrollment_count":46,"lead_sponsor_name":"Jun Zhang, MD, PhD","has_results":false},{"nct_id":"NCT03805841","title":"Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":41,"lead_sponsor_name":"Rain Oncology Inc","has_results":true},{"nct_id":"NCT04846452","title":"Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT06728852","title":"Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Li-kun Chen","has_results":false},{"nct_id":"NCT03713944","title":"Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":30,"lead_sponsor_name":"Nasser Hanna","has_results":true},{"nct_id":"NCT05617313","title":"Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":21,"lead_sponsor_name":"Jeffrey Clarke","has_results":false},{"nct_id":"NCT05891197","title":"A Biomarker Screening Protocol for Participants With Solid Tumors","phase":"","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Lyell Immunopharma, Inc.","has_results":false}],"total":13},"guidelines":[],"source":"Drug Landscape verified database"}